Vermillion to Present at the Piper Jaffray 30thAnnual Healthcare Conference
To access the full press release please click here
AUSTIN, Texas, November 20, 2018— Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced thatValerie Palmieri, President and CEO of Vermillion will present at the upcoming Piper Jaffray 30thAnnual Healthcare Conference taking place November 27-29 at the Lotte New York Palace Hotel in New York City.
Piper Jaffray 30thAnnual Healthcare ConferencePresentation Details
Date: Thursday, November 29
Time: 9:30 A.M. Eastern Time
Location: Lotte New York Palace Hotel
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases. The company’s initial in vitro diagnostic test, OVA1® (MIA), was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016, Vermillion received FDA clearance for Overa™, a Multivariate Index Assay 2nd Generation (MIA2G) test with significantly improved specificity and ease of use. For additional information, including published clinical trials, visit www.vermillion.com.
Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC